Clinical trialPhase 1Terminated
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer
- Outcome
- Stopped earlyCombined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects. (Other)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 11 November 2019
- Expected end
- 9 September 2021
- Enrollment
- 13 participants
- Sites
- 2
- Primary outcomes
- Rate of dose limiting toxicities of each subject
- Sponsor
- Industry
- Results posted
- No
- Last update
- 6 May 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.This phase IB trial is Multi-center and open。